| Dr Jeffrey M Welsch, MD | |
|
2414 Kohler Memorial Dr, Sheboygan, WI 53081-3129 | |
| (920) 457-4461 | |
| Not Available |
| Full Name | Dr Jeffrey M Welsch |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 28 Years |
| Location | 2414 Kohler Memorial Dr, Sheboygan, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841296092 | NPI | - | NPPES |
| 34189600 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 44343 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aurora Sheboygan Memorial Medical Ctr | Sheboygan, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aurora Medical Group, Inc. | 6709794258 | 3207 |
News Archive
Researchers from Sorbonne Université have been reviewing papers exploring different anti-COVID-19 drugs.
Cancer survival rates have improved across England, according to two new reports from the Office for National Statistics (ONS).But the reports also reveal that there are still gaps in survival, with patients from wealthy areas having a better chance of beating cancer than their poorer counterparts.
Doctors are gaining new leverage in the fight against lung injury caused by acid reflux. The paper by Bonnans et al., "Lipoxin A4 regulates bronchial epithelial cell responses to acid injury," appears in the April issue of The American Journal of Pathology and is accompanied by a commentary.
Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.
› Verified 4 days ago
| Entity Name | Aurora Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427271378 PECOS PAC ID: 6709794258 Enrollment ID: O20031105000725 |
News Archive
Researchers from Sorbonne Université have been reviewing papers exploring different anti-COVID-19 drugs.
Cancer survival rates have improved across England, according to two new reports from the Office for National Statistics (ONS).But the reports also reveal that there are still gaps in survival, with patients from wealthy areas having a better chance of beating cancer than their poorer counterparts.
Doctors are gaining new leverage in the fight against lung injury caused by acid reflux. The paper by Bonnans et al., "Lipoxin A4 regulates bronchial epithelial cell responses to acid injury," appears in the April issue of The American Journal of Pathology and is accompanied by a commentary.
Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey M Welsch, MD Po Box 735044, Milwaukee, WI 53215-2843 Ph: (920) 457-4461 | Dr Jeffrey M Welsch, MD 2414 Kohler Memorial Dr, Sheboygan, WI 53081-3129 Ph: (920) 457-4461 |
News Archive
Researchers from Sorbonne Université have been reviewing papers exploring different anti-COVID-19 drugs.
Cancer survival rates have improved across England, according to two new reports from the Office for National Statistics (ONS).But the reports also reveal that there are still gaps in survival, with patients from wealthy areas having a better chance of beating cancer than their poorer counterparts.
Doctors are gaining new leverage in the fight against lung injury caused by acid reflux. The paper by Bonnans et al., "Lipoxin A4 regulates bronchial epithelial cell responses to acid injury," appears in the April issue of The American Journal of Pathology and is accompanied by a commentary.
Savient Pharmaceuticals, Inc. provided an update on its activities directed toward the resubmission of its Biologics License Application (BLA) for KRYSTEXXA(TM) (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy and reaffirmed its belief that it continues to be on track for the filing of the BLA resubmission for KRYSTEXXA in the first quarter of 2010.
› Verified 4 days ago
Jeffrey M Tomasini, Urology Medicare: Accepting Medicare Assignments Practice Location: 2414 Kohler Memorial Dr, Sheboygan, WI 53081 Phone: 920-457-4461 | |
Dr. Gregory S Grose, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1414 N Taylor Dr, Ste 210, Sheboygan, WI 53081 Phone: 920-457-4858 Fax: 920-457-3650 | |
Dr. John P Hermann, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2414 Kohler Memorial Dr, Sheboygan, WI 53081 Phone: 920-457-4461 Fax: 920-459-1155 |